Daily Trades
- Dylan Jovine
Because small biotech stocks have sold off this year, the stock price doesn’t reflect the company’s business prospects, so I am banging the table again on this one.
- Dylan Jovine
I recommend selling shares of ON Semiconductor (SYM: ON) here at $78.95, a 116% gain from our recommended price of $36.44.
- Dylan Jovine
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
- Dylan Jovine
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
- Dylan Jovine
On November 18, MEI Pharma (SYM: MEIP) and their Japanese Big Pharma giant Kyowa Kirin announced solid results for their Lymphoma drug, zandelisib.
- Dylan Jovine
Education is witnessing a massive, transformational shift. In fact, the online learning category is expected to grow more than five times over the next seven years, according to IPO Edge, which is more than two times faster that e-commerce growth between 2014 and 2019.
- Dylan Jovine
Wanted to give you all a quick update on Clovis (SYM: CLVS) and MEI Pharma (SYM: MEIP). The iron rule of biotech investing is to bet on the science.
deal of the month
Categories
Insiders Are Selling! What Record-Low Insider Buying Signals for the Stock Market
Can Hurricane Season Create a Debt Crisis??
Hurricane Season & US Debt Crisis: Why Rising Insurance Costs Signal Bigger Problems
Recent posts
Tags
Connect with Us
- Dylan Jovine
Because small biotech stocks have sold off this year, the stock price doesn’t reflect the company’s business prospects, so I am banging the table again on this one.
- Dylan Jovine
I recommend selling shares of ON Semiconductor (SYM: ON) here at $78.95, a 116% gain from our recommended price of $36.44.
- Dylan Jovine
An aging population is demanding better treatment in an effort to live longer lives (I'm beginning to count myself among that population).
As we've detailed in these pages over the years, there's incredible new innovation in gene therapies, immuno-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs, such as Geographic Apathy.
- Dylan Jovine
I have an exciting recommendation for you this month: organ transplant firm, TransMedics (SYM: TMDX). It’s a bit outside of our normal focus on oncology and rare disease firms.
- Dylan Jovine
On November 18, MEI Pharma (SYM: MEIP) and their Japanese Big Pharma giant Kyowa Kirin announced solid results for their Lymphoma drug, zandelisib.
- Dylan Jovine
Education is witnessing a massive, transformational shift. In fact, the online learning category is expected to grow more than five times over the next seven years, according to IPO Edge, which is more than two times faster that e-commerce growth between 2014 and 2019.
- Dylan Jovine
Wanted to give you all a quick update on Clovis (SYM: CLVS) and MEI Pharma (SYM: MEIP). The iron rule of biotech investing is to bet on the science.
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.